BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 29550841)

  • 21. Preliminary clinical assessment of dynamic 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for evaluating the clinicopathological grade in patients with non-Hodgkin's lymphoma: a prospective study.
    Shinya T; Otomi Y; Dimitrakopoulou-Strauss A; Kubo M; Kondo M; Otomo M; Terazawa K; Bando Y; Harada M
    Nucl Med Commun; 2020 Jan; 41(1):26-33. PubMed ID: 31800508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does partial volume corrected maximum SUV based on count recovery coefficient in 3D-PET/CT correlate with clinical aggressiveness of non-Hodgkin's lymphoma?
    Tsujikawa T; Otsuka H; Morita N; Saegusa H; Kobayashi M; Okazawa H; Nishitani H
    Ann Nucl Med; 2008 Jan; 22(1):23-30. PubMed ID: 18250984
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Tan X; Sun X; Yuan H; He L; Ding C; Jiang L
    Hell J Nucl Med; 2022; 25(3):285-296. PubMed ID: 36507885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma.
    Shinya T; Fujii S; Asakura S; Taniguchi T; Yoshio K; Alafate A; Sato S; Yoshino T; Kanazawa S
    Ann Nucl Med; 2012 Oct; 26(8):616-21. PubMed ID: 22692457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma.
    Cho SF; Chang CC; Liu YC; Chang CS; Hsiao HH; Liu TC; Huang CT; Lin SF
    Kaohsiung J Med Sci; 2015 Mar; 31(3):130-7. PubMed ID: 25744235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Texture Indices of 18F-FDG PET/CT for Differentiating Squamous Cell Carcinoma and Non-Hodgkin's Lymphoma of the Oropharynx.
    Mitamura K; Norikane T; Yamamoto Y; Ihara-Nishishita A; Kobata T; Fujimoto K; Takami Y; Kudomi N; Hoshikawa H; Nishiyama Y
    Acta Med Okayama; 2021 Jun; 75(3):351-356. PubMed ID: 34176939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Correlation and Influencing Factors of SUVmax and Ki-67 in Non-Hodgkin Lymphoma].
    Li J; Zhao M; Yuan L; Liu Y; Ma N
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):136-140. PubMed ID: 35123616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. (18)F-FDG and (18)F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes.
    Rayamajhi SJ; Mittal BR; Maturu VN; Agarwal R; Bal A; Dey P; Shukla J; Gupta D
    Ann Nucl Med; 2016 Apr; 30(3):207-16. PubMed ID: 26661845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of contrast-enhanced ultrasound and PET/CT in assessment of extramedullary lymphoma.
    Jiang W; Xue H; Wang Q; Zhang X; Wang Z; Zhao C
    Eur J Radiol; 2018 Feb; 99():88-93. PubMed ID: 29362156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor Identification of Less Aggressive or Indolent Lymphoma With Whole-Body 11C-Acetate PET/CT.
    Tsuchiya J; Yamamoto M; Bae H; Oshima T; Yoneyama T; Miura O; Tateishi U
    Clin Nucl Med; 2019 Apr; 44(4):276-281. PubMed ID: 30688736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.
    Spaepen K; Stroobants S; Dupont P; Vandenberghe P; Thomas J; de Groot T; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
    Ann Oncol; 2002 Sep; 13(9):1356-63. PubMed ID: 12196360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis.
    Chen YK; Yeh CL; Tsui CC; Liang JA; Chen JH; Kao CH
    Clin Nucl Med; 2011 Jul; 36(7):553-9. PubMed ID: 21637057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
    Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
    J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 18F-FDG PET/computed tomography may predict the outcome of newly diagnosed indolent non-Hodgkin lymphoma in patients managed with initial 'watch-and-wait' approach.
    Luo Y; Zhang Y; Pan Q; Zhang Y; Li F
    Nucl Med Commun; 2020 Dec; 41(12):1283-1290. PubMed ID: 32925828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma.
    Bodet-Milin C; Kraeber-Bodéré F; Moreau P; Campion L; Dupas B; Le Gouill S
    Haematologica; 2008 Mar; 93(3):471-2. PubMed ID: 18310543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
    Reinhardt MJ; Herkel C; Altehoefer C; Finke J; Moser E
    Ann Oncol; 2005 Sep; 16(9):1524-9. PubMed ID: 15946979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients.
    Barrio M; Czernin J; Yeh MW; Palma Diaz MF; Gupta P; Allen-Auerbach M; Schiepers C; Herrmann K
    Nucl Med Commun; 2016 Dec; 37(12):1290-1296. PubMed ID: 27612034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.